At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 855 enrolled
Drug / intervention
Mitomycin, doxifluridine and cisplatin +1 moredrug
Likely dose
Mitomycin, doxifluridine and cisplatin 20mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma
In Brief
A Phase 3 clinical trial evaluating Mitomycin, doxifluridine and cisplatin and Mitomycin and doxifluridine for Stomach Cancer. Completed, enrolled 855 participants across 1 site.
Detailed Summary
This is a phase III randomized study designed to evaluate the efficacy of mitomycin, doxifluridine, and cisplatin compared to mitomycin and doxifluridine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Cancer
CountriesSouth Korea
CollaboratorsUlsan University Hospital, Hallym University Medical Center
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2002
First PostedFeb 2006
Primary CompletionNov 2007
Study CompletionDec 2009
TodayJul 2026
First PostedFeb 27, 2006
Enrollment StartFeb 1, 2002
Primary CompletionNov 1, 2007
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 20.3 years ago
Interventions
Mitomycin, doxifluridine and cisplatindrug
Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
Mitomycin and doxifluridinedrug
Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)